menu
    • menu
    [{"orgOrder":0,"company":"Plexium","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"IKZF2 transcription factor","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plexium \/ BVF Partners","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ BVF Partners"},{"orgOrder":0,"company":"Plexium","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"E3 ligase mediated proteasomal","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plexium \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ Amgen Inc"},{"orgOrder":0,"company":"Plexium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PLX-4545","moa":"IKZF2","graph1":"Oncology","graph2":"Phase I","graph3":"Plexium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Plexium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Plexium \/ Inapplicable"}]

    Find Oncology Clinical Drug Pipeline Developments & Deals by Plexium

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Plexium

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Plexium

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PLX-4545

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Plexium Initiates Dosing in Phase 1 Study of PLX-4545, a Potent and Selective Degrader of the Transcription Fa...

                            Details : PLX-4545 is an IKZF2 Inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of patients suffering from solid tumors.

                            Product Name : PLX-4545

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 12, 2023

                            Lead Product(s) : PLX-4545

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Plexium

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Plexium

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Amgen Inc

                            Deal Size : $500.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Amgen and Plexium Announce Multi-Year, Drug Discovery Collaboration to Identify Novel Targeted Protein Degrada...

                            Details : Under the terms of the agreement, the collaboration will initially focus on two programs with Amgen holding options to add additional programs. Amgen has a commercial license to each program that advances to a preclinical stage of development and commerc...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 02, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Amgen Inc

                            Deal Size : $500.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Plexium

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Plexium

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : BVF Partners

                            Deal Size : $102.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Plexium Announces $102m Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology...

                            Details : The proceeds from the financing will enable Plexium to accelerate its pipeline programs toward the clinic, including a molecular glue that selectively degrades the IKZF2 transcription factor, selective degraders of CDK2 and SMARCA2, and other undisclosed...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 23, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : BVF Partners

                            Deal Size : $102.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth